Ken Shain, MD, PhD, spoke about the dramatic impact of novel immunotherapies in the multiple myeloma treatment landscape, as well as other updates from the 2022 ASH Annual Meeting and Exposition.
Transcript:
Immunotherapies—meaning bispecifics and CAR T—are going to change the way we take care of our disease. We need to figure out how to make sure all patients will have access to these novel therapies, these novel immunotherapies, or these T cell–engaging therapies. We’re on the horizon of understanding what they mean clinically, and how they work in the context of the immune microenvironment.
Transcript edited for clarity.
FDA Approves Cilta-Cel for Relapsed/Refractory Myeloma After 1 Therapy
April 6th 2024The FDA has approved ciltacabtagene autoleucel for the treatment of adult patients with relapsed/refractory multiple myeloma who have received at least 1 prior line of treatment, including a proteasome inhibitor and an immunomodulatory agent, and are refractory to lenalidomide.
Relapsed/Refractory Multiple Myeloma Trial Updates From ASCO 2023
August 7th 2023Experts from Mayo Clinic and The University of Texas MD Anderson Cancer Center discuss results from multiple myeloma trials presented at the 2023 American Society of Clinical Oncology Annual Meeting and how they may apply to clinical practice.